Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma
Dudley M, Gross C, Somerville R, Hong Y, Schaub N, Rosati S, White D, Nathan D, Restifo N, Steinberg S, Wunderlich J, Kammula U, Sherry R, Yang J, Phan G, Hughes M, Laurencot C, Rosenberg S. Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. Journal Of Clinical Oncology 2013, 31: 2152-2159. PMID: 23650429, PMCID: PMC3731980, DOI: 10.1200/jco.2012.46.6441.Peer-Reviewed Original ResearchConceptsYoung tumor-infiltrating lymphocytesTumor-infiltrating lymphocytesAdoptive cell therapyCD4(+) lymphocytesCell therapyInterleukin-2High-dose IL-2 therapyAutologous tumor-infiltrating lymphocytesHigh-dose interleukin-2Infusion tumor-infiltrating lymphocytesResponse to autologous tumorTIL infusionIL-2 therapyImmunologic end pointsInterferon-gamma secretionSubgroup of patientsPeripheral blood lymphocytesResponse to treatmentLymphodepleted patientsLymphodepleting chemotherapyTIL productsTIL therapyAutologous tumorDesign trialMetastatic melanoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply